Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
T Cell Types and Functions01:24

T Cell Types and Functions

2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glomerular Injury Induced by Daily Exposure to the Low-Frequency Component of Environmental Noise via Endothelin Signaling in Mice.

Environmental science & technology·2026
Same author

Targeted Inhibition of mGlu5 Receptors in the Contralesional Hemisphere Improves Functional Recovery After Stroke.

Stroke·2026
Same author

Light-Regulated Agonists Spatiotemporally Activating the Vitamin D Receptor Mitigate Psoriasis-like Inflammation in Mice without Inducing Hypercalcemia.

ACS central science·2025
Same author

Sex Bias in IL-10 Production by Type I Regulatory T Cells Regulated by PI3K/mTOR Signaling.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Novae: a graph-based foundation model for spatial transcriptomics data.

Nature methods·2025
Same author

Emerging Risk: Intranasal Tin Exacerbates Allergic Rhinitis in Humans and Mice.

Allergy·2025

Related Experiment Video

Updated: Jan 18, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.0K

Conditional IL4I1 Inactivation Triggers Tumor-Associated Macrophage Reprogramming and CD8+ T-cell Reactivation to

Malvina Seradj1, Saniya Kari1, Anna Llebaria-Fabrias1

  • 1INSERM U1016, CNRS UMR 8104, Institut Cochin, Université Paris Cité, Paris, France.

Cancer Immunology Research
|January 15, 2026
PubMed
Summary
This summary is machine-generated.

The enzyme IL-4 induced gene 1 (IL4I1) in tumor-associated macrophages (TAMs) promotes melanoma immune escape. Inhibiting IL4I1 enhances anti-tumor immunity and delays melanoma progression, offering new immunotherapy strategies.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.2K

Related Experiment Videos

Last Updated: Jan 18, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.0K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.2K

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Tumor-associated macrophages (TAMs) are key immune cells in cancer, often linked to poor prognosis.
  • TAMs can adopt protumor properties through immunosuppressive enzyme expression.
  • IL-4 induced gene 1 (IL4I1) is an enzyme implicated in immune modulation within the tumor microenvironment.

Purpose of the Study:

  • To investigate the role of IL4I1 expressed by TAMs in melanoma progression.
  • To determine the impact of IL4I1 on TAM function and anti-tumor immunity.
  • To explore IL4I1 as a potential therapeutic target in melanoma immunotherapy.

Main Methods:

  • Analysis of IL4I1 expression in TAMs during spontaneous melanoma progression in murine models.
  • Genetic deletion of IL4I1 in macrophages to assess its in vivo effects on tumor growth and metastasis.
  • Pharmacological blockade of IL4I1 activity.
  • Assessment of TAM antigen-presenting capacity and CD8+ T cell functions.

Main Results:

  • IL4I1 expression was upregulated in TAM subsets during melanoma progression, controllable by cytokine co-neutralization.
  • Macrophage-specific IL4I1 deletion significantly delayed tumor onset and reduced metastatic spread.
  • Targeting IL4I1 enhanced TAM antigen presentation and restored CD8+ T cell proliferation and cytotoxicity.
  • Chemical IL4I1 blockade partially replicated these anti-tumor effects.

Conclusions:

  • IL4I1 plays a critical role in TAM-mediated immune evasion in melanoma.
  • IL4I1 inhibition represents a promising strategy to restore anti-tumor immunity in melanoma.
  • Targeting IL4I1 in TAMs holds potential for advancing cancer immunotherapy, particularly in IL4I1-expressing human tumors.